Rafael Holdings reported narrowed Q4 and FY26 net losses driven by lower admin costs and a gain on settlements. While Q4 Net Loss narrowed to $9.2M, full year R&D expenses increased due to Cyclo Therapeutics consolidation.
Rafael Holdings reported narrowed Q4 and FY26 net losses driven by lower admin costs and a gain on settlements. While Q4 Net Loss narrowed to $9.2M, full year R&D expenses increased due to Cyclo Therapeutics consolidation.